175 related articles for article (PubMed ID: 37455698)
1. Are Patients with HHV-8 Associated Castleman Disease Successfully Treated with Rituximab at Risk of Subsequently Developing HHV-8 Negative (Idiopathic) Castleman Disease?
Ha G; Kwong K; Tanaka B; Nishimura Y; Chong C
Eur J Case Rep Intern Med; 2023; 10(7):003904. PubMed ID: 37455698
[TBL] [Abstract][Full Text] [Related]
2. Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease.
Nabel CS; Sameroff S; Shilling D; Alapat D; Ruth JR; Kawano M; Sato Y; Stone K; Spetalen S; Valdivieso F; Feldman MD; Chadburn A; Fosså A; van Rhee F; Lipkin WI; Fajgenbaum DC
PLoS One; 2019; 14(6):e0218660. PubMed ID: 31242229
[TBL] [Abstract][Full Text] [Related]
3. Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.
Lang E; Sande B; Brodkin S; van Rhee F
Ther Adv Hematol; 2022; 13():20406207221082552. PubMed ID: 35251585
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Tolerance and Efficacy of Siltuximab (Anti-IL-6) in a Young Adult with Idiopathic Multicentric Castleman Disease During COVID-19.
Bedier H; Isnard S; Maedler-Kron C; Routy JP
Eur J Case Rep Intern Med; 2023; 10(12):004098. PubMed ID: 38077710
[TBL] [Abstract][Full Text] [Related]
5. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
Fajgenbaum DC
Blood; 2018 Nov; 132(22):2323-2330. PubMed ID: 30487129
[TBL] [Abstract][Full Text] [Related]
6. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.
Yu L; Tu M; Cortes J; Xu-Monette ZY; Miranda RN; Zhang J; Orlowski RZ; Neelapu S; Boddu PC; Akosile MA; Uldrick TS; Yarchoan R; Medeiros LJ; Li Y; Fajgenbaum DC; Young KH
Blood; 2017 Mar; 129(12):1658-1668. PubMed ID: 28100459
[TBL] [Abstract][Full Text] [Related]
7. From Castleman disease histopathological features to idiopathic multicentric Castleman disease: a multiparametric approach to exclude potential iMCD histopathological mimickers.
Rodriguez Merino L; Pomares AA; Arce JR; Montes-Moreno S
J Clin Pathol; 2024 Apr; 77(5):318-323. PubMed ID: 36690434
[TBL] [Abstract][Full Text] [Related]
8. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
Fajgenbaum DC
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):318-325. PubMed ID: 30504327
[TBL] [Abstract][Full Text] [Related]
9. Multicentric Castlemans disease. Symptoms, diagnostics and therapy.
Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Sandecká V; Krejčí M; Štork M; Ševčíková S; Král Z
Vnitr Lek; 2022; 68(1):41-53. PubMed ID: 35459346
[TBL] [Abstract][Full Text] [Related]
10. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.
Fajgenbaum DC; van Rhee F; Nabel CS
Blood; 2014 May; 123(19):2924-33. PubMed ID: 24622327
[TBL] [Abstract][Full Text] [Related]
11. An HHV-8 Positive HIV Negative Multicentric Castleman's Disease, who Responded well to Rituximab Alone.
Kounatidis D; Rontogianni D; Sampaziotis D; Vardaka M; Giatra C; Dolapsakis C; Margellou E; Vallianou NG
Cardiovasc Hematol Disord Drug Targets; 2020; 20(1):84-86. PubMed ID: 30827270
[TBL] [Abstract][Full Text] [Related]
12. The Potential Clinical Benefit of Tocilizumab Therapy for Patients with HHV-8-infected AIDS-related Multicentric Castleman Disease: A Case Report and Literature Review.
Barlingay G; Findakly D; Hartmann C; Amar S
Cureus; 2020 Apr; 12(4):e7589. PubMed ID: 32399323
[TBL] [Abstract][Full Text] [Related]
13. Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.
Fajgenbaum DC; Kurzrock R
Immunotherapy; 2016; 8(1):17-26. PubMed ID: 26634298
[TBL] [Abstract][Full Text] [Related]
14. The full spectrum of Castleman disease: 273 patients studied over 20 years.
Oksenhendler E; Boutboul D; Fajgenbaum D; Mirouse A; Fieschi C; Malphettes M; Vercellino L; Meignin V; Gérard L; Galicier L
Br J Haematol; 2018 Jan; 180(2):206-216. PubMed ID: 29143319
[TBL] [Abstract][Full Text] [Related]
15. A HHV-8 positive, HIV negative multicentric Castleman disease treated with R-CEOP chemotherapy and valganciclovir combination.
Kantarci FE; Eren R; Gündoğan C; Huq GE; Doğu MH; Suyanı E
J Infect Chemother; 2016 Jul; 22(7):483-5. PubMed ID: 26948831
[TBL] [Abstract][Full Text] [Related]
16. [Not Available].
Bertinchamp R; Terriou L
Rev Med Interne; 2022 Dec; 43(10S1):10S4-10S9. PubMed ID: 36657941
[TBL] [Abstract][Full Text] [Related]
17. Human herpesvirus 8-associated multicentric Castleman disease in a patient with advanced HIV infection: A case report.
Guayboon T; Chinthammitr Y; Sukpanichnant S; Horthongkham N; Angkasekwinai N
Medicine (Baltimore); 2021 Dec; 100(49):e28077. PubMed ID: 34889256
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in Castleman Disease.
Hoffmann C; Hentrich M; Tiemann M; Rosenwald A; Weber F; Willenbacher W; Hübel K
Oncol Res Treat; 2022; 45(11):693-704. PubMed ID: 36219975
[TBL] [Abstract][Full Text] [Related]
19. Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy.
Cohen PR; Nikanjam M; Kato S; Goodman AM; Kurzrock R
Cureus; 2020 Jul; 12(7):e8967. PubMed ID: 32766009
[TBL] [Abstract][Full Text] [Related]
20. [Recent advances in diagnosis and treatment of idiopathic multicentric Castleman disease].
Okamoto S
Rinsho Ketsueki; 2019; 60(9):1205-1211. PubMed ID: 31597845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
